Literature DB >> 29372372

Surgery for Hepatocellular Carcinoma in Patients with Child-Pugh B Cirrhosis: Hepatic Resection Versus Living Donor Liver Transplantation.

Norifumi Harimoto1, Tomoharu Yoshizumi2, Yukiko Fujimoto2, Takashi Motomura2, Youhei Mano2, Takeo Toshima2, Shinji Itoh2, Noboru Harada2, Toru Ikegami2, Hideaki Uchiyama2, Yuji Soejima2, Yoshihiko Maehara2.   

Abstract

BACKGROUND: Liver transplantation has been established as the optimal treatment for hepatocellular carcinoma in cirrhotic patients, but hepatic resection is also effective in patients with well-preserved liver function. Determining the suitable surgical treatment for patients with Child-Pugh class B cirrhosis is a more difficult challenge.
METHODS: We retrospectively compared the results of hepatic resection and living donor liver transplantation for hepatocellular carcinoma in 137 patients with Child-Pugh class B cirrhosis. The procedures were performed at Kyushu University Hospital from April 2014 through October 2016.
RESULTS: Patients who underwent hepatic resection were significantly older and had better liver function, larger tumor size, smaller number of tumors, and less surgical stress compared with patients who underwent living donor liver transplantation. The overall survival rate and the recurrence-free survival rate in patients with transplantation were significantly better than that in patients with resection. The multivariate analysis showed that recurrent hepatocellular carcinoma and microvascular invasion were significant prognostic factors for both overall and recurrence-free survival in the hepatic resection group. In the group with protein induced by vitamin K absence or antagonist-II ≥300 mAU/mL, both the overall survival curve and the recurrence-free survival curve in patients with living donor liver transplantation were not significantly different from those in patients with hepatic resection.
CONCLUSIONS: Living donor liver transplantation for hepatocellular carcinoma in patients with Child-Pugh class B cirrhosis was favorable under the condition of protein induced by vitamin K absence or antagonist-II <300 mAU/mL in selected recipients and donors. Hepatic resection for recurrent hepatocellular carcinoma and excessive blood loss should be avoided in patients with Child-Pugh class B cirrhosis.

Entities:  

Mesh:

Year:  2018        PMID: 29372372     DOI: 10.1007/s00268-018-4493-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  37 in total

Review 1.  Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

2.  Living donor hepatectomies with procedures to prevent biliary complications.

Authors:  Akinobu Taketomi; Kazutoyo Morita; Takeo Toshima; Kazuki Takeishi; Hiroto Kayashima; Mizuki Ninomiya; Hideaki Uchiyama; Yuji Soejima; Ken Shirabe; Yoshihko Maehara
Journal:  J Am Coll Surg       Date:  2010-07-02       Impact factor: 6.113

3.  Longterm favorable results of limited hepatic resections for patients with hepatocellular carcinoma: 20 years of experience.

Authors:  Yo-ichi Yamashita; Akinobu Taketomi; Shinji Itoh; Dai Kitagawa; Hiroto Kayashima; Norifumi Harimoto; Eiji Tsujita; Yosuke Kuroda; Yoshihiko Maehara
Journal:  J Am Coll Surg       Date:  2007-07       Impact factor: 6.113

4.  Repeat hepatectomy for recurrent hepatocellular carcinoma.

Authors:  Toshiyuki Itamoto; Hideki Nakahara; Hironobu Amano; Toshihiko Kohashi; Hideki Ohdan; Hirotaka Tashiro; Toshimasa Asahara
Journal:  Surgery       Date:  2007-05       Impact factor: 3.982

5.  Second hepatic resection for recurrent hepatocellular carcinoma.

Authors:  N Nagasue; H Yukaya; Y Ogawa; Y Sasaki; Y C Chang; K Niimi
Journal:  Br J Surg       Date:  1986-06       Impact factor: 6.939

6.  Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.

Authors:  Norifumi Harimoto; Ken Shirabe; Hidekazu Nakagawara; Takeo Toshima; Yo-Ichi Yamashita; Toru Ikegami; Tomoharu Yoshizumi; Yuji Soejima; Tetsuo Ikeda; Yoshihiko Maehara
Journal:  Transplantation       Date:  2013-12-15       Impact factor: 4.939

7.  Bacterial sepsis after living donor liver transplantation: the impact of early enteral nutrition.

Authors:  Toru Ikegami; Ken Shirabe; Shohei Yoshiya; Tomoharu Yoshizumi; Mizuki Ninomiya; Hideaki Uchiyama; Yuji Soejima; Yoshihiko Maehara
Journal:  J Am Coll Surg       Date:  2012-01-11       Impact factor: 6.113

8.  Surgical management of hepatocellular carcinoma in Child-Pugh class B cirrhotic patients: hepatic resection and/or microwave coagulation therapy versus living donor liver transplantation.

Authors:  Noboru Harada; Ken Shirabe; Yasuharu Ikeda; Daisuke Korenaga; Kenji Takenaka; Yoshihiko Maehara
Journal:  Ann Transplant       Date:  2012-12-31       Impact factor: 1.530

9.  Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation.

Authors:  Akinobu Taketomi; Takasuke Fukuhara; Kazutoyo Morita; Hiroto Kayashima; Mizuki Ninomiya; Yoichi Yamashita; Toru Ikegami; Hideaki Uchiyama; Tomoharu Yoshizumi; Yuji Soejima; Ken Shirabe; Yoshihko Maehara
Journal:  Ann Surg Oncol       Date:  2010-03-05       Impact factor: 5.344

10.  Pattern and management of recurrent hepatocellular carcinoma after liver transplantation.

Authors:  E Regalia; L R Fassati; U Valente; A Pulvirenti; I Damilano; G Dardano; F Montalto; J Coppa; V Mazzaferro
Journal:  J Hepatobiliary Pancreat Surg       Date:  1998
View more
  4 in total

1.  A Practical Nomogram and Risk Stratification System Predicting Cancer-Specific Survival for Hepatocellular Carcinoma Patients With Severe Liver Fibrosis.

Authors:  Dashuai Yang; Yang Su; Fangrui Zhao; Chen Chen; Kailiang Zhao; Xiangyun Xiong; Youming Ding
Journal:  Front Surg       Date:  2022-06-16

2.  Is partial hepatectomy a curable treatment option for hepatocellular carcinoma accompanied by cirrhosis? A meta-analysis and cure model analysis.

Authors:  Byungje Bae; Keera Kang; Sung Kyu Song; Chul-Woon Chung; Yongkeun Park
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-02-28

3.  Long-term outcomes of living-donor liver transplantation, hepatic resection, and local therapy for hepatocellular carcinoma with three <3-cm nodules in a single institute.

Authors:  Masaaki Hidaka; Takanobu Hara; Akihiko Soyama; Tomohiko Adachi; Hajime Matsushima; Takayuki Tanaka; Hideki Ishimaru; Hisamitsu Miyaaki; Kazuhiko Nakao; Susumu Eguchi
Journal:  JGH Open       Date:  2022-06-30

4.  Influence of Child-Pugh B7 and B8/9 cirrhosis on laparoscopic liver resection for hepatocellular carcinoma: a retrospective cohort study.

Authors:  Yukihiro Watanabe; Masayasu Aikawa; Tomotaka Kato; Kenichiro Takase; Yuichiro Watanabe; Katsuya Okada; Kojun Okamoto; Isamu Koyama
Journal:  Surg Endosc       Date:  2022-10-06       Impact factor: 3.453

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.